Effectiveness of dabrafenib in the treatment of patients with BRAF V600–mutated metastatic melanoma in a Named Patient Program
Salvador Martín‐Algarra(Clinica Universidad de Navarra), Michael Millward(University of Western Australia), Philippe Legenne(The University of Texas MD Anderson Cancer Center), Colin R. Lindsay(Apple (Israel)), Pier Francesco Ferrucci(MultiMedica), Barbara Merelli(Ospedale Papa Giovanni XXIII), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Jonathan Cebon(La Trobe University), Rebecca A. Hinshelwood(Apple (Israel)), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Klaus Freivogel, Giuseppe Tonini(Campus Bio Medico University Hospital), Mike Lau(Novartis (Switzerland)), Paola Queirolo, Bart Neyns(Universitair Ziekenhuis Brussel), Lindi D Dalland(Agence Nationale pour l'Emploi), Soizick Mesnage(Auckland City Hospital), Dara Stein(EVRAZ (United Kingdom)), Victoria Atkinson(Greenslopes Private Hospital), Massimo Aglietta(Verizon (United States)), Helena Linardou(Metropolitan Hospital)
Cited by 11
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k